Human antibodies that bind human TNFalpha

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd= 10~8 M or less), a slow off rate for hTNFa dissociation (e.g., K ~ff10- 3 sec~' or less) and neutr...

Full description

Saved in:
Bibliographic Details
Main Authors SALFELD, JOCHEN G, ALLEN, DEBORAH J, MCGUINESS, BRIAN T, ROBERTS, ANDREW J, HOOGENBOOM, HENDRICUS R. J. M, KAYMAKCALAN, ZEHR, VAUGHAN, TRISTAN J, MANKOVICH, JOHN A, LABKOVSKY, BORIS, SCHOENHAUT, DAVID, WHITE, MICHAEL, SAKORAFAS, PAUL, WILTON, ALISON J
Format Patent
LanguageEnglish
Published 28.11.2013
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd= 10~8 M or less), a slow off rate for hTNFa dissociation (e.g., K ~ff10- 3 sec~' or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Bibliography:Application Number: AU20130257402